{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "../sources/BEQ_2301_OVERALL_multi.pdf", "file_path": "../sources/BEQ_2301_OVERALL_multi.pdf", "total_pages": 113, "format": "PDF 1.7", "title": "Presentazione standard di PowerPoint", "author": "Key-Stone", "subject": "", "keywords": "\"country\": \"Europe\",\"year\": 2023,\"target\": \"clinic\"", "creator": "Microsoft\u00ae PowerPoint\u00ae per Microsoft 365", "producer": "Microsoft\u00ae PowerPoint\u00ae per Microsoft 365", "creationDate": "D:20230602170729+02'00'", "modDate": "D:20230602170729+02'00'", "trapped": ""}, "page_content": " how respondents associate different pharmaceutical companies with various attributes across a sample of 1018 cases. the attributes include \"high reputation,\" \"historical/traditional,\" \"scientific,\" and \"excellent/the best.\" for the attribute \"excellent/the best,\" the top selections are: **3m** with 17% of respondents associating them with this attribute. **dentsply sirona** with 14%. **gc** at 8%. the distribution is relatively low for most other companies, with responses of 4% or less. specifically, these companies include: **ivoclar** at 7%. **kavo** and **straumann** are tied at 4%. **kerr** is at 2%. other companies like **kulzer**, **coltene**, **nobel biotec**, **kuraray noritake**, **tokuyama**, and **voco**, among others, are at 2% or fewer. for the category labeled \"don't know / no answer,\" 6% of respondents provide this response. the majority of respondents, representing 20%, select \"other\" as the chosen attribute. the remaining percentage is equally split among the listed pharmaceutical companies. overall, the image portrays a comprehensive", "type": "Document"}}